Enteroviruses alone, excluding the poliovirus, cause about 10 to 15 million infections in the United States each year. Tens of thousands of individuals are hospitalized each year for illnesses caused by enteroviruses. Enterovirus D68 (EV-D68, EV68, HEV68) is a member of the Picornaviridae family, an enterovirus. First isolated in California in 1962 and once considered rare, EV-D68 has been on a worldwide upswing in the 21st century.
In 2014, the United States experienced a nationwide outbreak of EV-D68 associated with severe respiratory illness. From mid-August 2014 to January 15, 2015, the CDC or state public health laboratories confirmed 1,153 total cases of respiratory illness caused by EV-D68 in 49 states and the District of Columbia. Almost all of the confirmed cases were among children, many of whom had asthma or a history of wheezing. Additionally, there were likely millions of mild EV-D68 infections for which individuals did not seek medical treatment and/or get tested.
The CDC received about 2,600 specimens for enterovirus laboratory testing during 2014, which is substantially more than usual. About 36% of those tested positive for EV-D68. About 33% tested positive for an enterovirus or rhinovirus other than EV-D68. EV-D68 was detected in specimens from 14 patients who died and had samples submitted for testing. State and local officials have the authority to determine and release information about the cause of these deaths.
The pain and suffering caused by the enteroviruses and the upsurge specifically in EV-D68 infections has caused the world to pause, backup and investigate retrospectively why this upsurge in activity and how better can we as healthcare providers prevent EV-D68 infections in the future before EV-D68 raises its ugly head again.
After completing this course, the learner will be able to meet the following objectives:
State the modes of transmission of EV-D68.
Describe infection control measures recommended to prevent the spread of EV-D68 infections in healthcare and non-healthcare settings
Relate the risk factors identified during the health history which predispose individuals to enteroviral/EV-D68 infections.
Describe the signs and symptoms of EV-D68 infection.
Describe healthcare provider’s responsibility to report clusters of severe respiratory illness to local and state health departments.
Relate the treatment regimen for individuals experiencing EV-D68 infection.
Relate educational strategies healthcare providers can utilize to teach individuals how to prevent EV-D68 infection.
Describe acute flaccid myelitis including signs and symptoms, testing, diagnosis, treatments, outcomes and possible causations.
Enteroviruses affect millions of people worldwide each year. They are often found in the respiratory secretions (e.g., saliva, sputum, or nasal mucus) and stool of an infected individual. Historically, poliomyelitis was the most significant disease caused by an enterovirus i.e. the poliovirus.
There are 64 non-polio enteroviruses that can cause disease in humans: 23 Coxsackie A viruses, 6 Coxsackie B viruses, 28 echoviruses, and 5 other enteroviruses. Poliovirus, as well as, coxsackie and echovirus are spread through the fecal-oral route. Infection can result in a wide variety of symptoms ranging from mild respiratory illness i.e. the common cold, hand, foot and mouth disease, acute hemorrhagicconjunctivitis, aseptic meningitis, myocarditis, severe neonatalsepsis-like disease, and acute flaccid myelitis.
Enteroviruses are members of the Picornaviridae family (Table 1), a large and diverse group of small RNA viruses characterized by a positive-sense single-stranded RNA (ssRNA) associated with several human and mammalian diseases. All enteroviruses contain a genome of approximately 7,500 bases and are known to have a high mutation rate due to low-fidelity replication and frequent recombination. After infection of the host cell, the genome is translated in a cap-independent manner into a single polyprotein, which is subsequently processed by virus-encoded proteases into the structural capsid proteins and the nonstructural proteins, which are mainly involved in the replication of the virus.
Serologic studies have distinguished 71 human enterovirus serotypes on the basis of antibody neutralization tests. Additional antigenic variants have been defined within several of the serotypes on the basis of reduced or nonreciprocal cross-neutralization between variant strains.
On the basis of their pathogenesis in humans and animals, the enteroviruses were originally classified into four groups: Polioviruses, Coxsackie A viruses (CA), Coxsackie B viruses (CB), and Echoviruses. It was quickly realized that there were significant overlaps in the biological properties of viruses in the different groups. Enteroviruses isolated more recently are named with a system of species designation and consecutive numbers: EV-D68, EV-B69, EV-D70, EV-A71, etc.
|Group:||Group IV ((+)ssRNA)|
The enterovirus genus includes the following twelve species:
Within these twelve species are the serotypes:
EV-D68 (Table 2) is one of more than one hundred types of enteroviruses (Table 1), as discussed previously. It is unenveloped. Unlike all other enteroviruses, EV-D68 displays acid lability and a lower optimum growth temperature, both characteristic features of the human rhinoviruses. It was previously called human rhinovirus 87 by some researchers.
Enterovirus 68 (EV-D68, HEV68, EV68) was first isolated in California in 1962 from four children diagnosed with bronchiolitis and pneumonia. EV-D68 has been rarely reported since that time. As such, the full spectrum of illness that it can cause is unknown.
1962 – 2005
Since EV-D68 was discovered through 2005, there were only 26 confirmed reports of the virus to the CDC.
2008 - 2010
Six clusters (equal to or more than 10 cases) or outbreaks between 2008 - 2010 associated with EV-D68 occurred in the Philippines, Japan, the Netherlands, and the states of Georgia, Pennsylvania and Arizona in the United States. EV-D68 infection presented with symptoms of respiratory illness ranging from relatively mild illness that did not require hospitalization to severe illness requiring intensive care and mechanical ventilation.
The Centers for Disease Control and Prevention (CDC) learned of these clusters of EV-D68 from public health agencies requesting consultation or diagnostic assistance and from reports presented at scientific conferences. In each cluster, EV-D68 was diagnosed by reverse transcription-polymerase chain reaction (RT-PCR) testing targeting the 5'-nontranslated region, followed by partial sequencing of the structural protein genes, VP4-VP2, VP1, or both, to give definitive, enterovirus type-specific information.
2009 – 2013
EV-D68 has rarely been reported in the United States. The National Enterovirus Surveillance System only received 79 EV-D68 reports during 2009–2013.
2012 - 2013
EV-D68 was found in 2 of 5 children during a 2012/13 cluster of polio-like disease in California.
In August 2014, EV-D68 caused clusters of respiratory disease in the United States. According to the Division of Viral Diseases at the National Center for Immunization and Respiratory Diseases EV-D68 "is one of the most rarely reported serotypes, with only 26 reports throughout the 36-year study period (1970 through 2006)."
The outbreak began in 11, mostly Midwestern, states and was first confirmed in Kansas City, Missouri, and Chicago, Illinois.
By mid-September 2014 there were 145 suspected cases, including Colorado, Louisiana, Alabama, New York, New Jersey, North Carolina, Michigan, Missouri, Iowa, Illinois, Montana, Kentucky, Kansas, Oklahoma, Indiana, Connecticut, Massachusetts, Rhode Island, and Wisconsin. One case involved a previously asthmatic non-immunocompromised adult. In Canada in September 2014, 49 cases of the virus were confirmed in Alberta, three in British Columbia, and over 100 in Ontario. Health officials reported Los Angeles County's first case of EV-D68 on October 1, 2014. By October 2, 6 more cases had been reported in California: four in San Diego County, and one each in Ventura and Alameda counties.
From mid-August to December 18, 2014, the CDC or state public health laboratories had confirmed a total of 1,152 people in 49 states and the District of Columbia with respiratory illness caused by EV-D68. Five children died.
In the United States, people are more likely to get infected with enteroviruses in the summer and fall. EV-D68 cases have been described to occur late in the enterovirus season, which is typically during the warm months, from summer to autumn (August and September in the Northern hemisphere).
EV-D68 can shed from an infected person's respiratory secretions, such as saliva, nasal mucus, or sputum for 1 to 3 weeks or less. Infected people can shed the virus even if they are asymptomatic.
The virus likely spreads from person to person when an infected person coughs, sneezes, or touches objects or surfaces that have the virus on them and then touches their own eyes, mouth or nose.
EV-D68 almost exclusively causes respiratory illness which may vary from mild to severe. Respiratory symptoms are more acute among children than adults. Infants, children and teenagers, especially if they have a history of asthma or reactive airway disease can require a trip to the emergency department for treatment and possible admission.
In adults, the symptoms may not be as severe, but in the confirmed cases of EV-D68 from 2008 to 2010, the median length of time adults were hospitalized ranged from 1.5 to five days.
Healthcare providers should consider EV-D68 as a possible cause of acute, unexplained severe respiratory illness.
Initial symptoms are resemble those of the common cold including:
Progression of the disease may lead to more serious symptoms including:
Like all enteroviruses, EV-D68 may also cause:
When seeing patients, especially children, with respiratory illness, healthcare providers should be aware of EV-D68 as a potential cause. They should consider laboratory testing of respiratory specimens for enteroviruses when the cause of infection in severely ill patients is unclear.
Many hospitals and/or clinics can test suspected patients for enteroviruses, but most are not able to do the testing needed to determine the type of enterovirus. Healthcare providers can approach their state health department for such testing. Healthcare providers should report clusters of severe respiratory illness to state and local health departments.
The CDC recommends that healthcare providers:
EV-D68 can only be diagnosed by doing specific laboratory tests on specimens from a patient’s nose and throat.
Many hospitals and some physicians’ offices can test ill patients to see if they have an enterovirus infection. However, most cannot do specific testing to determine the type of enterovirus, like EV-D68. The CDC and some state health departments can do this sort of testing.
On October 14, 2014, the CDC started using a new, faster laboratory test for detecting EV-D68, allowing the CDC to test and report results within a few days of receiving specimens. The CDC’s new laboratory test is a “real-time” reverse transcription polymerase chain reaction, or rRT-PCR, and it identifies all strains of EV-D68 that were seen this past summer and fall. The new test has fewer and shorter steps than the test that the CDC and some states were using for the EV-D68 2014 outbreak. Also, the new test allows more specimens to be tested at the same time.
Since the outbreak of EV-D68 began in August, the CDC has tested 1163 specimens submitted from around the country. Of the specimens tested by the CDC laboratory from August 1 to October 10, about half have tested positive for EV-D68. About one third have tested positive for a rhinovirus or an enterovirus other than EV-D68. The new laboratory test will allow the CDC to process the approximately one-thousand remaining specimens at a much faster rate.
The CDC Picornavirus Laboratory from mid-September to mid-October 2014 developed and evaluated the EV-D68-specific rRT-PCR assay. The assay and protocol are primarily focused on evaluating respiratory disease due to EV-D68.
For protocols about using the EV-D68 Real-Time RT-PCR assay, please see:
Before sending specimens for diagnostic and molecular typing:
and complete specimen submission form 50.34
There is no specific treatment and no vaccine, so EV-D68 has to run its course. There are no antiviral medications currently available for people who become infected with EV-D68. The antiviral drugs pleconaril, pocapavir, and vapendavir have significant activity against a wide range of enteroviruses and rhinoviruses. The CDC has tested these drugs for activity against currently circulating strains of EV-D68, and none of them has activity against EV-D68 at clinically relevant concentrations. A 2015 study suggested the antiviral drug pleconaril may be useful for the treatment of EV-D68.
Clinical care is directed against symptoms (symptomatic treatment): bronchodilators, oxygen therapy up to and including mechanical ventilation, antibiotics for coinfections where appropriate, pain control if necessary, fever control if necessary. Most people recover completely. However, some need to be hospitalized, and some have died as a result of the virus.
Five EV-D68 paralysis cases were unsuccessfully treated with steroids, intravenous immunoglobulin and/or plasma exchange. The treatments had no apparent benefit as no recovery of motor function was seen.
Healthcare providers in healthcare settings should strive to prevent the spread of EV-D68:
Infection control precautions should include Standard, Contact, and Droplet Precautions.
Although non-enveloped viruses such as EV-D68 may be less susceptible to alcohol than enveloped viruses or vegetative bacteria, alcohol-based hand rub (ABHR) offers benefits in skin tolerance, compliance, and, especially when combined with glove use, overall effectiveness for a wide variety of healthcare pathogens. Therefore, upon removal and prior to donning gloves, perform hand hygiene using either ABHR or soap and water.
As EV-D68 is a non-enveloped virus, environmental disinfection of surfaces in healthcare settings should be performed using a hospital-grade disinfectant with an EPA label claim for any of several non-enveloped viruses (e.g. norovirus, poliovirus, rhinovirus). Disinfectant products should be used in accordance with the manufacturer’s instructions for the specific label claim and in a manner consistent with environmental infection control recommendations.
Infection control recommendations for other than health care settings such as home, office, schools etc. include Clorox products. Clorox has a broad portfolio of EPA-registered surface disinfectants that can be used to clean and disinfect frequently touched surfaces. Although currently Clorox does not have any products that have been tested against EV-D68, the following products meet the criteria established by the CDC. (Table 3)
|Criteria established by the CDC: Must be an EPA-registered disinfectant with claims against: |
|EPA Reg. No.||Product Names|
Clorox Clean-Up Cleaner with Bleach
Clorox Clean-Up Cleaner + Bleach1
Clorox Disinfecting Bathroom Cleaner
Tilex Bathroom Cleaner
Clorox Commercial Solutions Clorox Disinfecting Bathroom Cleaner
Clorox Commercial Solutions Tilex Soap Scum Remover & Disinfectant
Clorox Disinfecting Wipes
Clorox Disinfecting Wipes1
Clorox Disinfecting Wipes3
Clorox Disinfecting Wipes4
Clorox Toilet Bowl Cleaner with Bleach
Clorox Toilet Bowl Cleaner – Clinging Bleach Gel
Clorox Commercial Solutions Clorox Germicidal Bleach1
Clorox Germicidal Bleach 1
Clorox Kitchen Cleaner + Bleach1
Clorox CareConcepts Germicidal Bleach Spray
Clorox Healthcare Bleach Germicidal Cleaner
Dispatch Hospital Cleaner Disinfectant Towels with Bleach
Clorox CareConcepts Germicidal Bleach Wipes
Clorox Commercial Solutions Clorox Disinfecting Wipes
Clorox CareConcepts Germicidal Non-Bleach Wipes
Clorox Healthcare Bleach Germicidal Wipes
Clorox Commercial Solutions Clorox Toilet Bowl Cleaner with Bleach1
Clorox Commercial Solutions Clorox Clean-Up Disinfectant Cleaner with Bleach1
Clorox Broad Spectrum Quaternary Disinfectant Cleaner
Clorox CareConcepts Germicidal Non-Bleach Spray1
Clorox Commercial Solutions Clorox Disinfecting Spray
Clorox Commercial Solutions Clorox Hydrogen Peroxide Disinfecting Cleaner
Clorox Healthcare Hydrogen Peroxide Cleaner Disinfectant
Clorox Commercial Solutions Clorox Hydrogen Peroxide Disinfecting Wipes
Clorox Healthcare Hydrogen Peroxide Cleaner Disinfectant Wipes
Clorox CareConcepts Germicidal Bleach
Clorox Commercial Solutions Clorox 4-in-1 Disinfectant & Sanitizer
Clorox Healthcare Citrace Hospital Disinfectant & Deodorizer
Clorox CareConcepts Disinfecting & Deodorizing Spray
Clorox 4 in One Disinfecting Spray
Clorox Pro Quaternary All-Purpose Disinfectant Cleaner1
Although there are no vaccines to prevent EV-D68 infections, healthcare providers should encourage all patients to follow these prevention steps:
Children/adults with asthma or suffering from reactive airway disease are at greater risk for severe symptoms from EV-D68 and other respiratory illnesses. The CDC recommends that healthcare providers:
Information on cases and outbreaks of enterovirus infection is collected in the United States using two surveillance systems:
The CDC continues to:
The CDC obtained one complete genomic sequence and six nearly complete genomic sequences from viruses representing the three known strains of EV-D68 that are causing infection at this time. Comparison of these sequences to sequences from previous years shows they are genetically related to strains of EV-D68 that were detected in previous years in the United States, Europe, and Asia. The CDC has submitted the sequences to GenBank to make them available to the scientific community for further testing and analysis.
On October 14, 2014 the CDC started using a new, faster laboratory test for detecting EV-D68, allowing the CDC to test and report results within a few days of receiving specimens. The CDC’s laboratory test is a “real-time” reverse transcription polymerase chain reaction, or rRT-PCR, and it identifies all strains of EV-D68 that circulated during summer and fall 2014. It has fewer and shorter steps than the test that the CDC and some states were using previously during this EV-D68 outbreak.
The CDC has made the protocols publicly available on its EV-D68 for Health Care Professionals web page and is exploring options for providing test kits to state public health labs.
Acute flaccid myelitis has been formerly described as “acute flaccid paralysis with anterior myelitis” or “polio-like syndrome”. It is an acute neurologic illness with focal limb weakness which occurs in children. Its etiology is unknown.
EV-D68 has been suspected as the leading candidate for the cause of this rare polio-like syndrome since two California children who tested positive for the virus had muscle weakness or paralysis of one or more limbs reaching peak severity within 48 hours of onset. "Recovery of motor function was poor at 6-month follow-up."
As of October 2014 the CDC was investigating 10 cases of paralysis and/or cranial dysfunction in Colorado and other reports around the country, coinciding with the increase in EV-D68 activity. As of October 23, 2014 it was believed that the actual number of cases might be 100 or more.
A summary of the condition was issued by the United States Centers for Disease Control as part of a September 26, 2014 health advisory:
August 9 – September 17, 2014
October 13, 2014
October 21, 2014
October 23, 2014
Of 64 patients meeting the CDC criteria before October 29, 2014, 80% had had a preceding respiratory illness and 75% reported fever in the days leading up to limb weakness, the onset of which was generally abrupt. By November 20, 2014 the number of confirmed cases stood at 88 from 29 states.
The suspected cause of the 2014 cases is a strain of enterovirus D. Most enteroviruses and rhinoviruses cause only common cold symptoms. The September 26, 2014 the CDC health advisory that described the cases continued with the identification of EV-D68, a member of the enterovirus D species, as a suspected cause.
Cerebral spinal fluid (CSF) testing to date had been negative for West Nile virus and other enteroviruses, including poliovirus. Nasopharyngeal specimens were positive for rhinovirus/enterovirus in six out of eight patients that were tested. Of the six positive specimens, four were typed as EV-D68, and the other two were pending typing results. Testing of other specimens continued. Eight out of nine children had been confirmed to be up to date on polio vaccinations. Epidemiologic and laboratory investigations of these cases are ongoing.
The Morbidity and Mortality Weekly Report (MMWR) noted the difficulty of establishing causation by EV-D68:
Avindra Nath, clinical director of the National Institute of Neurological Disorders and Stroke and president of the International Society for NeuroVirology, compared the situation to the prolonged investigations that led to confirmation of HIV as the cause of AIDS. In response to the suggestion that the enterovirus might be taking over the role of polio, Nath said that enterovirus 68 was far less virulent and spread much more slowly than polio, and that, unlike in polio, only a few cases of paralysis were seen per thousand children infected. He also suggested that adults with respiratory diseases should also be evaluated for neurologic deficits, and that infectious disease should be considered as a cause when patients presented with neurologic symptoms.
There is no known treatment for acute flaccid myelitis. It has not been established whether steroids are helpful or harmful. Plasmaphoresis, intravenous immunoglobulin, and experimental antiviral drugs have been attempted on a trial basis, but have not been reported to be effective.
On November 7, 2014 the CDC issued "Interim Considerations for Clinical Management of Patients with Acute Flaccid Myelitis", based on "consensus guidance drawn from experts in infectious diseases, neurology, pediatrics, critical care medicine, public health epidemiology and virology." Mark Sawyer of the American Academy of Pediatrics, who contributed to the guidance, was quoted by the organization's newsletter:
Six of ten children in Denver were sent home for outpatient treatment. Some with mild symptoms have recovered from temporary limb weakness, while the fate of those more severely affected remains unclear. Intensive physical therapy and occupational therapy may be beneficial for recovery.
In summary, the Enterovirus genus includes twelve species within which are the serotypes for each species. The serotypes are astounding in number. EV-D68 is only one of the total of known serotypes and during the 2014 EV-D68 outbreak at least three strains of EV-D68 have been discovered. Years of research and development will ensue before a vaccine will be discovered to stop the enteroviruses in their tracts. Until then treatment for EV-D68 infection will remain symptomatic. So with the coming of the enterovirus season, summer and fall 2015, remember EV-D68 usually rears its ugly head in August and September. So, PREVENTION, PREVENTION, PREVENTION proactively.
Enterovirus D68 in the U.S., 2014 (The CDC).
Enterovirus D68 for Health Care Professionals (The CDC).
CDC health alert (HAN) (http://emergency.cdc.gov/han/han00369.asp) dated September 12, 2014.
Hand Hygiene in Healthcare Settings (http://www.cdc.gov/handhygeine).
Respiratory Illness and Enterovirus D68: Clinical Guidance, (http://www.medscape.com/viewarticle/831790), September 19, 2014.
Enterovirus D68 in the United States: Epidemiology, Diagnosis & Treatment, (http://www.bt.cdc.gov/coca/calls/2014/callinfo 0914.asp) COCA Call, September 16, 2014.
Severe Respiratory Illness Associated with Enterovirus D68-Missouri and Illinois, 2014 (http://www.cdc.gov.mmwr/preview/mmwrhtml/mm63e0908a1.htm)MMWR, September 8, 2014.
Clusters of Acute Respiratory Illness Associated with Human Enterovirus 68-Asia, Europe and United States, 2008-2010. (http://www.cdc.gov/mmwR/preview/mmwrhtml/mm6038a1.htm) MMWR, September 30, 2011.
Enterovirus D68 (EV-D68) Resources (http://www.cdc.gov/non-polio-enterovirus/resources-EVD68.html).
Brown, Eryn (23 February 2014). "Mysterious polio-like illnesses reported in some California children". LA Times. Retrieved 25 February 2014.
Carville, Olivia (24 September 2014). "100 Ontario children infected with vicious EV-D68 virus". Toronto Star. Retrieved 25 September 2014.
"Children's Hospital: 10th Colorado child has paralysis-like symptoms; may be tied to Enterovirus 68". Thedenverchannel.com. 2014-09-29.
"CDC releases guidance on acute flaccid myelitis". AAP News (American Academy of Pediatrics). 2014-11-12.
Dan Hurley (2014-10-24). "The mysterious polio-like disease affecting American kids". The Atlantic.
"Enterovirus D68: 3 confirmed cases in B.C.'s Lower Mainland". CBC News. 16 September 2014. Retrieved 17 September 2014.
"Enterovirus D68: Eight California cases of rare illness; some patients suffer paralysis". Retrieved 14 October 2014.
Enterovirus D68 and Paralysis (2014-10-03). "Enterovirus D68 and Paralysis". The Disease Daily/Outbreak News/Healthmap.
Gillian Mohney (2014-09-06). "Respiratory Virus Sickening Children in Colorado". ABC News.
Herriman, Robert (23 September 2014). "Confirmed enterovirus D68 cases in Alberta rise to 49". Outbreak News Today. The Global Dispatch, Inc. Retrieved 27 September 2014.
"Is CDC Hiding Enterovirus Link To Illegal Alien Kids? 536 Comments". Investor's Business Daily. 2014-10-17. Retrieved October 22, 2014.
Malone, Scott (1 October 2014). "Rhode Island child with Enterovirus dies after infection: officials". Reuters. Retrieved 6 October 2014.
Mohney, Gillian (4 October 2014). "Medical Examiner Finds NJ Preschooler Died Due to Enterovirus 68". ABCNews. Retrieved 6 October 2014.
"Mysterious Polio-Like Illness Found in California Children". Voice of America. February 24, 2014. Retrieved 24 February 2014.
"Acute neurologic illness with focal limb weakness of unknown etiology in children". United States Centers for Disease Control. 2014-09-26.
CDC (2003). "Guidelines for Environmental Infection Control in Health-Care Facilities". Retrieved 17 September 2014.
CDC. Enterovirus surveillance—United States, 2002–2004. MMWR. 2006; 55(06); 153-156.
CDC. Enterovirus surveillance—United States, 1970–2005. MMWR. 2006; 55(No. SS-08).
CDC. Enterovirus surveillance—United States, 2000–2001. MMWR. 2002;22;51(46):1047-9.
CDC. Enterovirus surveillance—United States, 1997–1999. MMWR. 2000; 49(40):913-6.
Clusters of Acute Respiratory Illness Associated with Human Enterovirus 68-Asia, Europe and United States, 2008-2010, MMWR 2011; 60:1301-4.
"Enterovirus D68 in the United States, 2014". CDC. 2014-10-24
"Investigation of Acute Neurologic Illness with Focal Limb Weakness of Unknown Etiology in Children, Fall 2014". CDC. Retrieved 2014-11-21.
"Neurologic Illness with Limb Weakness in Children". CDC. 2014-10-03.
"Non-Polio Enterovirus Infection: States with Lab-confirmed Enterovirus D68 - CDC". Retrieved 14 October 2014.
"Non-Polio Enterovirus Infections". CDC. 8 September 2014. Retrieved 9 September 2014.
"Severe Respiratory Illness Associated with Enterovirus D68 — Missouri and Illinois, 2014". Morbidity and Mortality Weekly Report (MMWR) (CDC). 63(Early Release): 1–2. September 8, 2014. Retrieved 9 September 2014.
"An Update on Outbreak of Paralysis in US: Acute Flaccid Myelitis". The transverse myelitis association. 2014-10-16. (audio)
Alexandra Roux,Sabeen Lulu, Emmanuelle Waubant,Carol Glaser,Keith Van Haren (April 29, 2014). "A Polio-Like Syndrome in California: Clinical, Radiologic, and Serologic Evaluation of Five Children Identified by a Statewide Laboratory over a Twelve-Months Period". Poster Session III: Child Neurology and Developmental Neurology III. Retrieved 9 September 2014.
Blomqvist, S.; Savolainen, C.; Raman, L.; Roivainen, M.; Hovi, T. (2002). "Human Rhinovirus 87 and Enterovirus 68 Represent a Unique Serotype with Rhinovirus and Enterovirus Features". Journal of Clinical Microbiology 40 (11): 4218. doi:10.1128/JCM.40.11.4218-4223.2002. PMID 12409401.
"CDC continues investigation of neurologic illness; will issue guidelines". AAP News (The American Academy of Pediatrics). 3 October 2014. Retrieved 6 October 2014.
Dan Hurley (2014-10-21). "Cases of acute flaccid myelitis in children suspected in multiple states, prompting comparisons to polio". American Academy of Neurology.
Imamura T, Fuji N, Suzuki A, et al. Enterovirus 68 among children with severe acute respiratory infection, Philippines. Emerg Infect Dis 2011;7:1430–5.
INTERNATIONAL COMMITTEE ON TAXONOMY OF VIRUSES (March 2010). "ICTV 2009 MASTER SPECIES LIST VERSION 4".
Kaida A, Kubo H, Sekiguchi J, et al. Detection of enterovirus 68 from infants with respiratory infection and febrile convulsion [Japanese]. Infect Agents Surveil Rep 2010;31:300.
Kreuter JD, Barnes A, McCarthy JE, et al. A fatal central nervous system enterovirus 68 infection. Arch Pathol Lab Med 2011;135:793–6.
Lauinger, I. L.; Bible, J. M.; Halligan, E. P.; Aarons, E. J.; MacMahon, E.; Tong, C. Y. W. (2012). "Lineages, Sub-Lineages and Variants of Enterovirus 68 in Recent Outbreaks". PLoS ONE 7 (4): e36005.
Marx A, Glass JD, Sutter RW. Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance. Epidemiol Rev 2000;22:298–316.
Merkle I, van Ooij MJ, van Kuppeveld FJ, et al. (2002). "Biological Significance of a Human Enterovirus B-Specific RNA Element in the 3' Nontranslated Region". J. Virol. 76 (19): 9900–9.
Nix WA, Maher K, Johansson ES, Niklasson B, Lindberg AM, Pallansch MA, Oberste MS. Detection of all known parechoviruses by real time—PCR. J Clin Microbiol. 2008;46(8):2519-2524.
Nix WA, Maher K, Pallansch MA, Oberste, MS. Parechovirus typing in clinical specimens by nested or semi-nested VP1 PCR coupled with sequencing. J Clin Virol. 2010;48:202-207.
Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol. 2006;44(8):2698-2704.
Oberste MS, Maher K, Schnurr D, et al. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J Gen Virol 2004;85:2577–84.
Oberste MS, Maher K, Flemister MR, Marchetti G, Kilpatrick DR, Pallansch MA. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J Clin Microbiol. 2000;38(3):1170-4.
Oberste MS, Penaranda S, Rogers SL, Henderson E, Nix WA. Comparative evaluation of Taqman real-time PCR and semi-nested VP1 PCR for detection of enteroviruses in clinical specimens. J Clin Virol. 2010;49:73-74.
Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol . 1999;73(3):1941-8.
Oberste MS, Nix WA, Maher K, Pallansch MA. Improved molecular identification of enteroviruses by RT—PCR and amplicon sequencing. J Clin Virol. 2003;26(3):375-7.
Petitjean-Lecherbonnier J, Dina J, Nguyen E, et al. Molecular diagnosis of respiratory enterovirus infections: use of PCR and molecular identification for a best approach of the main circulating strains during 2008. Pathol Biol (Paris) 2011;59:113–21.
Robert Roos (2014-10-03). "Role of EV-D68 in polio-like illnesses still unclear". Center for Infectious Disease Research and Policy.
Ryu H, Yukie S, Yoshinori K, et al. Detection of enterovirus 68 from the throat swab of a patient who died of cardiopulmonary arrest of unknown origin [Japanese]. Infect Agents Surveil Rep 2010;31:361.
Schieble JH, Fox VL, Lennette EH. A probable new human picornavirus associated with respiratory disease. Am J Epidemiol 1967;85:297–310.
Seroka, Rachel (23 February 2014). "Mysterious polio-like illness found in 5 California children". American Academy of Neurology. Retrieved 24 February 2014.
Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee. "2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings". p. 225. Retrieved 17 September 2014.
Strikas RA, Anderson LJ, Parker RA. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970–1983. J Infect Dis 1986;153:346–51.
Tokarz, R.; Firth, C.; Madhi, S. A.; Howie, S. R. C.; Wu, W.; Sall, A. A.; Haq, S.; Briese, T.; Lipkin, W. I. (2012). "Worldwide emergence of multiple clades of enterovirus 68". Journal of General Virology 93: 1952
Wikswo M, Khetsuriani N, Fowlkes A, et al. Increased activity of coxsackievirus B1 strains associated with severe disease among young infants in the United States, 2007-2008. Clin Infect Dis. 2009;49(5):e44-51.
This course is applicable for the following professions:
Advanced Registered Nurse Practitioner (ARNP), Clinical Nurse Specialist (CNS), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Midwife (MW), Registered Nurse (RN)
Advance Practice Nurse Pharmacology Credit, CPD: Practice Effectively, Infection Control/Disease, Medical Surgical